Movers and SHAKERS
|Current Price||$12.67 ↑ 0.10|
|52wk Range||$2.89 - $35.10|
|ADVANCED MARKET DATA|
Advanced Market DataAltimmune Inc. (ALT)
910 Clopper Road
Gaithersburg, MD 20878
Altimmune Inc is a United States-based clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. The firm's product candidates include NasoVAX, HepTcell, SparVax-L, NasoShield, and Oncosyn. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.
Altimmune (NASDAQ: ALT) began clinical testing of its intranasal COVID-19 vaccine candidate earlier this year. It now has company. The University of Oxford recently began testing a nasal-spray version of the COVID-19 vaccine that it developed with big drugmaker AstraZeneca (NASDAQ: AZN) . In this Motley Fool Live video recorded on March 31, 2021 , Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not an intranasal COVID-19 vaccine from AstraZeneca could zap Altimmune's prospects.
For further details see:Could AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects?
Altimmune Inc. Corporate Filings
Altimmune Inc. Corporate Events
Altimmune Inc. Press Releases / News Feed
No reports available